Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Finasteride use is linked to a lower risk of bladder cancer, especially in Caucasians and Hispanics.

Researchers created a simple tool to predict bladder blockage from prostate enlargement using urine flow rate and prostate volume.

New drugs and combination therapies are improving treatment for lower urinary tract symptoms.

Venlafaxine can cause urinary incontinence in rare cases.

Early intervention for acute urinary retention can reduce costs and improve care.

Unexplained anemia in older men may be linked to urological issues like urinary retention.

Early detection and treatment of urinary symptoms can help maintain functional ability in older adults.

Finasteride does not prevent bladder cancer.

Metabolic syndrome linked to urinary symptoms; hair loss not significant.

Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.

Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.

Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.

A woman developed severe bladder inflammation after cancer treatment with Cytoxan.

AMN can cause bladder problems due to nerve damage.

Teaching men with simple bladder problems self-management skills can improve their symptoms and quality of life.

Adrenomyeloneuropathy (AMN) can cause bladder problems due to nerve damage.

Researchers developed a mouse model that successfully mimics the bladder damage seen in humans after radiation therapy.

PRP injections effectively improve stress urinary incontinence in women.

The IPP index is linked to storage symptoms and leftover urine, and may help manage urinary tract symptoms.

Tamsulosin and solifenacin together effectively reduce symptoms in BPH patients.

Eosinophilic cystitis is often misdiagnosed, but accurate diagnosis and treatment improve outcomes.

Intravenous cyclophosphamide effectively treated steroid-resistant lupus cystitis and peritonitis.

5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.

5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.

Combining medications is more effective for treating benign prostatic syndrome symptoms.

Urinary PSA could be an early marker for enlarged prostate.

Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.

Thermobalancing therapy is safe and effective for treating enlarged prostates.

Hair loss, prostate size, and urinary issues are related due to androgen effects.

Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.